Varex Imaging (VREX) Q3 2025: Industrial Orders Hit $55M YTD as Segment Mix Drives Margin Shift
Industrial order momentum and medical segment stability offset macro trade volatility for Varex Imaging this quarter, as segment mix and tariff impacts shape profitability. Management’s execution on supply chain localization and product innovation underpins a cautiously optimistic outlook, but gross margin headwinds and capital allocation priorities remain key investor watchpoints heading into fiscal 2026.
Summary
- Industrial Segment Drives Order Book: Cargo systems and security screening demand propelled industrial orders above $55 million YTD.
- Margin Compression Signals Mix Shift: Lower-margin industrial equipment and tariff costs pressured gross margin guidance, despite strong volume.
- Photon Counting Pathway Clarifies: Commercialization timelines for next-gen detectors remain intact, but meaningful medical revenue is several years out.
Performance Analysis
Varex Imaging delivered Q3 revenue above the high end of guidance, driven by robust industrial segment performance and a recovery in China following tariff relief. The industrial segment contributed 30% of total revenue, up 1% year over year, while the medical segment accounted for the remaining 70% but declined 4% as radiography and dental held steady, CT showed strength, and fluoroscopy lagged. China sales rebounded, representing 15% of total revenue and increasing 4% YoY after customers resumed shipments when tariffs normalized.
Non-GAAP gross margin improved 100 basis points YoY to 34%, benefiting from favorable mix and lower-than-expected tariff costs. However, guidance for Q4 anticipates margin contraction to 32-33%, reflecting a greater proportion of lower-margin industrial hardware and persistent tariff headwinds. Operating expenses were well-managed on a non-GAAP basis, but a $94 million non-cash goodwill impairment drove a GAAP net loss, highlighting sensitivity to market valuation. Cash declined by $73 million due to the paydown of $200 million in convertible notes, with net debt leverage now at two times adjusted EBITDA.
- Order Book Strength: Year-to-date cargo system orders exceeded $55 million, supporting industrial backlog and visibility.
- Medical Segment Recovery: Inventory destocking has largely normalized, and procedure volumes appear stable, setting up for a more predictable FY26.
- Tariff and Mix Pressure: Despite passing some costs to customers, tariffs and a higher share of equipment sales are expected to weigh on margins near term.
Management’s disciplined capital allocation and progress on supply chain localization initiatives are helping to offset macro volatility, but investors should monitor ongoing margin pressure and the timeline for higher-margin service revenue realization.
Executive Commentary
"We are pleased to report that third quarter revenue of $203 million was above high end of our guidance. During this quarter, we saw continued strength in our industrial segment and our revenue in China was better than forecasted and in line with the recent quarters."
Sunny Sanyal, President & Chief Executive Officer
"Gross margin benefited from lower than previously anticipated impact from tariff-related expenses... As a result of this non-cash charge, operating loss was reported at $81 million net loss of $89 million, and GAAP EPS loss of $2.15 per share based on a fully diluted 42 million share count."
Sam Maheshwari, Chief Financial Officer
Strategic Positioning
1. Industrial Segment Expansion
Industrial x-ray and cargo systems are now a clear growth engine, with year-to-date bookings surpassing $55 million. The company’s vertically integrated model—building both linear accelerators and detectors—enables rapid response to global security and inspection demand. Recent investments in UK and US facilities are designed to support this growth, with management signaling readiness for larger, $25 million-plus orders if won.
2. Supply Chain Localization and Tariff Mitigation
Varex is executing a multi-pronged supply chain strategy to reduce tariff exposure and improve cost competitiveness. Efforts include expanding manufacturing in India for value-tier radiographic components, establishing bonded warehouses, and pursuing local-for-local production models. While these initiatives are only midway to completion, early benefits are visible in lower-than-expected tariff costs this quarter, though full impact will take several quarters to materialize.
3. Photon Counting Commercialization
Photon counting technology, a next-generation x-ray detector innovation, remains a long-term growth lever. Industrial applications are already contributing incremental revenue, but medical commercialization is gated by OEM integration timelines. Management reiterated its target of $150 million in photon counting revenue by 2029, with two-thirds from medical and one-third from industrial, but cautioned that meaningful medical contributions will not materialize until after customer system launches post-2027.
4. Capital Structure and Cash Allocation
The repayment of $200 million in convertible notes reduced overall debt burden and positions the company for future refinancing. Management intends to rebuild cash reserves ahead of the next debt tranche due in 18 months, targeting $300-350 million in gross debt, signaling a conservative approach to leverage as growth investments continue.
5. Service Revenue Upside
Management expects future margin uplift as the installed base of industrial equipment ages out of warranty, shifting revenue mix toward higher-margin service contracts. The lag between equipment delivery and service revenue realization is roughly 18-24 months, positioning the company for potential margin expansion in fiscal 2026 and beyond.
Key Considerations
This quarter underscores the importance of segment mix, supply chain agility, and capital discipline as Varex navigates a volatile macro and trade backdrop.
Key Considerations:
- Industrial Pipeline Visibility: Robust order intake and a healthy project funnel in cargo inspection systems provide near-term revenue visibility.
- Medical Segment Normalization: Inventory destocking is largely complete, and procedure volume trends are stable, supporting a more predictable base for FY26.
- Tariff Pass-Through Limitations: While some tariff costs are passed to customers, not all can be mitigated, directly impacting gross margin guidance.
- Photon Counting Ramp Timeline: Material medical revenue from photon counting is unlikely before 2028, with current progress focused on OEM integration and industrial adoption.
- Cash and Leverage Priorities: Near-term cash flow will be directed toward rebuilding reserves and managing refinancing risk, limiting flexibility for aggressive capital deployment.
Risks
Persistent trade volatility, tariff escalation, and region-specific regulatory shifts remain material risks, especially for China and cross-border sales. Gross margin is exposed to unfavorable segment mix and incomplete tariff pass-through, while delays in photon counting commercialization or large order timing could disrupt growth expectations. Investors should also monitor capital allocation discipline as leverage and cash balances fluctuate with order fulfillment cycles.
Forward Outlook
For Q4 2025, Varex guided to:
- Revenue between $210 and $230 million
- Non-GAAP EPS between $0.10 and $0.30
For full-year 2025, management maintained guidance:
- Non-GAAP gross margin of 32-33% for Q4, reflecting lower-margin industrial mix and ongoing tariff impact
Management highlighted several factors that will shape results:
- Industrial order fulfillment and medical backlog normalization are expected to drive sequential growth
- Tariff and supply chain initiatives are progressing but will not fully offset cost headwinds in the near term
Takeaways
Varex Imaging’s Q3 performance demonstrates resilience in the face of macro volatility, with industrial segment momentum and medical normalization providing a base for FY26 growth.
- Order Book Momentum: YTD industrial orders and a healthy medical backlog support near-term revenue visibility, but margin pressure from mix and tariffs will persist into Q4.
- Photon Counting Remains a Long Game: Progress with OEM partners is encouraging, but investors should temper near-term expectations for material medical revenue.
- Margin Recovery Hinges on Service Mix and Supply Chain Execution: The path to higher margins depends on the successful transition from equipment sales to service contracts and further progress on localization and tariff mitigation.
Conclusion
Varex Imaging enters fiscal Q4 with strong industrial momentum and a stabilizing medical segment, but faces continued gross margin headwinds from segment mix and tariffs. Disciplined capital allocation and supply chain localization remain central to the investment case, while the photon counting roadmap offers long-term optionality for patient investors.
Industry Read-Through
Varex’s industrial strength and supply chain localization efforts highlight a broader trend among imaging and security equipment providers: vertical integration and regional manufacturing are increasingly essential to mitigate trade volatility and maintain margin. Tariff impacts and the lag between equipment and service revenue are common challenges for capital equipment businesses across healthcare and security sectors. Photon counting’s slow commercialization underscores the long lead times for next-gen imaging adoption, a dynamic relevant for all medtech and industrial imaging peers.